321 related articles for article (PubMed ID: 24704776)
1. Measuring serum levels of high-mobility group box 1 by enzyme-linked immunosorbent assay does not identify bacterial infections in patients with systemic lupus erythematosus.
Tang KT; Hsieh TY; Chen YM; Hsieh CW; Chen YH; Chen DY
Lupus; 2014 Aug; 23(9):926-34. PubMed ID: 24704776
[TBL] [Abstract][Full Text] [Related]
2. Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus.
Wirestam L; Schierbeck H; Skogh T; Gunnarsson I; Ottosson L; Erlandsson-Harris H; Wetterö J; Sjöwall C
Arthritis Res Ther; 2015 Nov; 17():338. PubMed ID: 26596890
[TBL] [Abstract][Full Text] [Related]
3. Anti-high mobility group box 1 (anti-HMGB1) antibodies are not related to the occurrence of cutaneous lesions in systemic lupus erythematosus.
Tan G; Zhu N; Shi Z; Meng Z; Yu M; Li K; Yin J; Wei K; Mi X; Wang L
Scand J Rheumatol; 2015; 44(2):150-6. PubMed ID: 25439526
[TBL] [Abstract][Full Text] [Related]
4. The use of procalcitonin determinations in evaluation of systemic lupus erythematosus.
Quintana G; Medina YF; Rojas C; Fernandez A; Restrepo JF; Rondon F; Iglesias A
J Clin Rheumatol; 2008 Jun; 14(3):138-42. PubMed ID: 18525431
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus.
Schaper F; de Leeuw K; Horst G; Maas F; Bootsma H; Heeringa P; Limburg PC; Westra J
Clin Exp Immunol; 2017 Jun; 188(3):412-419. PubMed ID: 28245520
[TBL] [Abstract][Full Text] [Related]
6. Association of anti-CLIC2 and anti-HMGB1 autoantibodies with higher disease activity in systemic lupus erythematosus patients.
Syahidatulamali CS; Wan Syamimee WG; Azwany YN; Wong KK; Che Maraina CH
J Postgrad Med; 2017; 63(4):257-261. PubMed ID: 28862243
[TBL] [Abstract][Full Text] [Related]
7. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.
Bobek D; Grčević D; Kovačić N; Lukić IK; Jelušić M
Pediatr Rheumatol Online J; 2014; 12():50. PubMed ID: 25516724
[TBL] [Abstract][Full Text] [Related]
8. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus.
Li J; Xie H; Wen T; Liu H; Zhu W; Chen X
J Rheumatol; 2010 Apr; 37(4):766-75. PubMed ID: 20110525
[TBL] [Abstract][Full Text] [Related]
9. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus.
Abdulahad DA; Westra J; Bijzet J; Limburg PC; Kallenberg CG; Bijl M
Arthritis Res Ther; 2011 May; 13(3):R71. PubMed ID: 21548924
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin.
Kim HA; Jeon JY; An JM; Koh BR; Suh CH
J Rheumatol; 2012 Apr; 39(4):728-34. PubMed ID: 22337236
[TBL] [Abstract][Full Text] [Related]
11. Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.
Závada J; Uher M; Svobodová R; Olejárová M; Hušáková M; Ciferská H; Hulejová H; Tomčík M; Šenolt L; Vencovský J
Arthritis Res Ther; 2015 Nov; 17():341. PubMed ID: 26608564
[TBL] [Abstract][Full Text] [Related]
12. High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study.
Gaïni S; Pedersen SS; Koldkjaer OG; Pedersen C; Møller HJ
Crit Care; 2007; 11(2):R32. PubMed ID: 17346334
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of serum high-mobility group box-1 in pediatric systemic lupus erythematosus.
Hossny E; El-Ghoneimy D; Soliman DA; Ashour A
Int J Rheum Dis; 2019 Aug; 22(8):1402-1409. PubMed ID: 30938057
[TBL] [Abstract][Full Text] [Related]
14. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus.
Firooz N; Albert DA; Wallace DJ; Ishimori M; Berel D; Weisman MH
Lupus; 2011 May; 20(6):588-97. PubMed ID: 21436216
[TBL] [Abstract][Full Text] [Related]
15. Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus.
Lanoix JP; Bourgeois AM; Schmidt J; Desblache J; Salle V; Smail A; Mazière JC; Betsou F; Choukroun G; Duhaut P; Ducroix JP
Lupus; 2011 Feb; 20(2):125-30. PubMed ID: 20937623
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous changes in serum HMGB1 and IFN-α levels and in LAIR-1 expression on plasmatoid dendritic cells of patients with juvenile SLE. New therapeutic options?
Kanakoudi-Tsakalidou F; Farmaki E; Tzimouli V; Taparkou A; Paterakis G; Trachana M; Pratsidou-Gertsi P; Nalbanti P; Papachristou F
Lupus; 2014 Mar; 23(3):305-12. PubMed ID: 24399813
[TBL] [Abstract][Full Text] [Related]
17. Microbiological and immunological profile of patients with severe lupus flares related to bloodstream infections: a retrospective cohort study.
Torres-Ruiz J; Barrera-Vargas A; Ortiz-Hernández R; Alcocer-Varela J; Ponce-de-León A; Gómez-Martín D
Lupus; 2018 Feb; 27(2):312-318. PubMed ID: 28699377
[TBL] [Abstract][Full Text] [Related]
18. Serum high-mobility group box 1 is correlated with interferon-α and may predict disease activity in patients with systemic lupus erythematosus.
Tanaka A; Ito T; Kibata K; Inagaki-Katashiba N; Amuro H; Nishizawa T; Son Y; Ozaki Y; Nomura S
Lupus; 2019 Aug; 28(9):1120-1127. PubMed ID: 31299881
[TBL] [Abstract][Full Text] [Related]
19. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial.
Mok CC; Ying SK; Ma KM; Wong CK
Lupus; 2013 Dec; 22(14):1470-8. PubMed ID: 24113197
[TBL] [Abstract][Full Text] [Related]
20. Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis.
Yasuda T; Ueda T; Takeyama Y; Shinzeki M; Sawa H; Nakajima T; Ajiki T; Fujino Y; Suzuki Y; Kuroda Y
Pancreas; 2006 Nov; 33(4):359-63. PubMed ID: 17079940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
